Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma

Brain Tumor Pathology

Volumn 29, Issue 2, 2012, Pages 87-95

  Utsuki, Satoshi ^a   Oka, Hidehiro ^a   Miyajima, Yoshiteru ^a   Kijima, Chihiro ^a   Yasui, Yoshie ^a   Fujii, Kiyotaka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebellar glioblastoma; EGFR; IDH1; P53; Secondary glioblastoma

Indexed keywords

BETA INTERFERON; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; PROTEIN P53; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN NECROSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; CEREBELLAR GLIOBLASTOMA; CLINICAL EXAMINATION; DEATH; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PSEUDOPALISADING NECROSIS; SUPRATENTORIAL GLIOBLASTOMA; TUMOR DIFFERENTIATION; TUMOR RECURRENCE;

ADULT; AGED; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPRATENTORIAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862770952     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-011-0070-0     Document Type: Article

References (28)

1. Committee of Brain Tumor Registry of Japan (2003) Report of brain tumor registry of Japan (1984-2000). Part I. General features of brain tumors. Neurol Med Chir (Tokyo) 49 (Suppl):S1-S25
2. Weber DC, Miller RC, Villa S et al (2006) Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys 66:179-186 (Pubitemid 44175667)
3. BozićB, Rotim K, Kogler A et al (2009) Cerebellar glioblastoma in the elderly-case report. Acta Clin Croat 48:175-178
4. Kuroiwa T, Numaguchi Y, Rothman MI et al (1995) Posterior fossa glioblastoma multiforme: MR findings. AJNR Am J Neuroradiol 16:583-589
5. Zito JL, Siva A, Smith TW et al (1983) Glioblastoma of the cerebellum. Computed tomographic and pathologic considerations. Surg Neurol 19:373-378 (Pubitemid 13115230)
6. Bristot R, Santoro A, Raco A et al (1999) Malignant cerebellar astrocytomas: clinico-pathological remarks on 10 cases. J Neurosurg Sci 43:271-276 (Pubitemid 30322190)
7. Chamberlain MC, Silver P, Levin VA (1990) Poorly differentiated gliomas of the cerebellum, a study of 18 patients. Cancer 65:337-340 (Pubitemid 20035363)
8. Dialilian HR, Hall WA (1998) Malignant gliomas of the cerebellum: an analytic review. J Neuro-Oncol 36:247-257 (Pubitemid 28075043)
9. Gupta V, Goval A, Sinha S et al (2003) Glioblastoma of the cerebellum. A report of 3 cases. J Neurosurg Sci 47:157-164
10. Tamaki T, Eguchi T, Sakamoto M et al (2004) Glioblastoma multiforme of the cerebellum in an elderly man. J Chin Med Assoc 67:301-302
11. Akimoto J, Fukami S, Tsutsumi M et al (2009) Radiopathological characteristics of cerebellar malignant glioma in adults. Brain Tumor Pathol 26:59-68
12. Kawarabuki K, Ohta T, Hashimoto N et al (2005) Cerebellar glioblastoma genetically defined as a secondary one. Clin Neuropathol 24:64-68 (Pubitemid 40388664)
13. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469-474
14. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453 (Pubitemid 47339290)
15. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007
16. Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254
17. Nagpal J, Jamoona A, Gulati ND et al (2006) Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res 26:4633-4639 (Pubitemid 46032092)
18. Ruano Y, Ribalta T, de Lope AR et al (2009) Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol 131:257-263
19. Watanabe K, Tachibana O, Sata K et al (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-224 (Pubitemid 26246377)
20. Saito T, Hama S, Kajiwara Y et al (2006) Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res 26:1351-1357
21. Grahovac G, Tomac D, Lambasa S et al (2009) Cerebellar glioblastomas: pathophysiology, clinical presentation and management. Acta Neurochir (Wien) 151:653-657
22. Cohen-Gadol AA, DiLuna ML, Bannykh SI et al (2004) Nonenhancing de novo glioblastoma: report of two cases. Neurosurg Rev 27:281-285 (Pubitemid 39350195)
23. Moore-Stovall J, Venkatesh R (1993) Serial nonenhancing magnetic resonance imaging scans of high grade glioblastoma multiforme. J Natl Med Assoc 85:122-128
24. Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466-2474
25. Zimmer C, Ivancevic V, Klingebiel R et al (2003) Advanced brain tumor imaging in unusual non-enhancing malignant gliomas. Klin Neuroradiol 13:88-91 (Pubitemid 36818575)
26. Kulkarni AV, Becker LE, Jay V et al (1999) Primary cerebellar glioblastomas multiforme in children. Report of four cases. J Neurosurg 90:546-550 (Pubitemid 29104606)
27. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
28. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of Temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumour Group. J Clin Oncol 17:2762-2771 (Pubitemid 29415233)